Globus Medical Q1 EPS Forecast Decreased by Roth Capital

Globus Medical, Inc. (NYSE:GMED) – Research analysts at Roth Capital decreased their Q1 2025 EPS estimates for shares of Globus Medical in a research report issued on Thursday, March 13th. Roth Capital analyst J. Wittes now expects that the medical device company will post earnings per share of $0.71 for the quarter, down from their previous estimate of $0.74. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Roth Capital also issued estimates for Globus Medical’s Q4 2025 earnings at $1.01 EPS.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, February 20th. The medical device company reported $0.84 EPS for the quarter, beating the consensus estimate of $0.74 by $0.10. The firm had revenue of $657.29 million during the quarter, compared to analyst estimates of $646.19 million. Globus Medical had a net margin of 4.09% and a return on equity of 10.83%.

GMED has been the subject of a number of other reports. Roth Mkm lifted their price objective on shares of Globus Medical from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 17th. Canaccord Genuity Group raised their price target on shares of Globus Medical from $92.00 to $101.00 and gave the company a “buy” rating in a report on Friday, January 10th. BTIG Research raised their price target on shares of Globus Medical from $87.00 to $91.00 and gave the company a “buy” rating in a report on Thursday, December 12th. Morgan Stanley raised shares of Globus Medical from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $83.00 to $100.00 in a report on Monday, December 2nd. Finally, Truist Financial raised their price target on shares of Globus Medical from $85.00 to $90.00 and gave the company a “hold” rating in a report on Wednesday, December 18th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Globus Medical presently has an average rating of “Moderate Buy” and a consensus target price of $97.82.

Globus Medical Stock Up 2.2 %

Shares of GMED stock opened at $71.21 on Friday. The company has a 50 day moving average of $84.86 and a 200-day moving average of $79.74. Globus Medical has a 12-month low of $49.33 and a 12-month high of $94.93. The firm has a market cap of $9.79 billion, a P/E ratio of 94.94, a PEG ratio of 1.61 and a beta of 1.19.

Insiders Place Their Bets

In other Globus Medical news, CFO Keith W. Pfeil sold 14,167 shares of the business’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $88.29, for a total value of $1,250,804.43. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 18.54% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Globus Medical

A number of hedge funds have recently modified their holdings of GMED. Norges Bank purchased a new position in shares of Globus Medical during the fourth quarter valued at about $117,102,000. RTW Investments LP purchased a new position in shares of Globus Medical during the fourth quarter valued at about $80,394,000. Iron Triangle Partners LP purchased a new position in shares of Globus Medical during the fourth quarter valued at about $69,808,000. Polar Capital Holdings Plc purchased a new position in shares of Globus Medical during the fourth quarter valued at about $63,762,000. Finally, Raymond James Financial Inc. purchased a new position in shares of Globus Medical during the fourth quarter valued at about $58,405,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.